Helus Pharma names Mark Lawson independent board chair
CYBN•Helus Pharma named Mark Lawson independent board chair. Co-founders Eric So and Paul Glavine left their executive and consulting roles effective October 26, 2026, and So was named chairman emeritus.
1. Board leadership change
Mark Lawson became independent board chair, bringing more than 20 years of experience in private equity and investment banking. Co-founders Eric So and Paul Glavine left their executive and consulting roles effective October 26, 2026; So, formerly president and executive chairman, was named chairman emeritus.
